GROUP PHARMACOKINETICS OF FLUCONAZOLE IN PATIENTS WITH SEVERE INFECTION

Authors

  • Lu Yao 1 Department of Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou, China. 2 Department of Pharmaceutics, Kweichow Moutai Hospital, Renhuai, Zunyi 563000, Guizhou, China. 3 Guizhou Children's Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou, China. 4 School of Pharmacy, Zunyi Medical University, Zunyi 563000, Guizhou, China. 5 Zhijin County People's Hospital, Bijie 552102, Guizhou, China.
  • Wei Bu 1 Department of Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou, China. 2 Department of Pharmaceutics, Kweichow Moutai Hospital, Renhuai, Zunyi 563000, Guizhou, China. 3 Guizhou Children's Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou, China. 4 School of Pharmacy, Zunyi Medical University, Zunyi 563000, Guizhou, China. 5 Zhijin County People's Hospital, Bijie 552102, Guizhou, China.
  • Min Luo Department of Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou, China , School of Pharmacy, Zunyi Medical University, Zunyi 563000, Guizhou, China , Zhijin County People's Hospital, Bijie 552102, Guizhou, China
  • Liu Shi Department of Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou, China , School of Pharmacy, Zunyi Medical University, Zunyi 563000, Guizhou, China
  • HongBo Xu Guizhou Children's Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou, China
  • WenMei Liang Department of Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou, China
  • Yan Chen Guizhou Children's Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou, China
  • Tao Chen Department of Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou, China
  • Bao Fu (Corresponding Author) Department of Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou, China
  • Lei Gong Department of Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou, China , Department of Pharmaceutics, Kweichow Moutai Hospital, Renhuai, Zunyi 563000, Guizhou, China

Keywords:

Voriconazole, Population pharmacokinetics, Exposure-response relationship

Abstract

Objective: The aim was to investigate the population pharmacokinetics (PopPK) model of Vorticamole (VRC), identify significant covariates and corresponding dose optimization strategies in the existing clinical patient VRC PopPK model, and explore the characteristics of the existing VRC PopPK model. Methods: We searched the PubMed database for clinical PopPK studies of VRC using the nonlinear mixed-effects method from the establishment of the database to May 2025, and screened the relevant references. Results: A total of 29 studies that met the inclusion criteria were finally included. One-compartment and two-compartment models were reported in 21 and 7 studies, respectively, as the best models to describe the PopPK of VRC, and one study used a three-compartment model. More than 40 covariates were included in the screening, with the most common covariates being CYP2C19 phenotype and body weight, and ALB being a secondary covariate. The typical volume of distribution in adult and pediatric patients was similar, but the estimated clearance in pediatric patients was significantly higher than that in adult patients, and the estimated bioavailability in pediatric patients was significantly lower than that in adult patients. The typical values of voriconazole clearance and total apparent volume of distribution exhibit substantial variability, ranging from 2.29–7.35 L/h and 76–194 L, respectively. Twenty-four studies used the exponential model as the basic model to describe the inter-individual variation. Only three studies used external methods to evaluate the model. Conclusion: First, this paper emphasizes the broadness and variability of the estimated PopPK parameters of VRC and provides the covariates that affect the clearance and apparent volume of distribution in such patients. Second, external evaluation of PopPK models should be conducted, and the predictive performance of various models should be further compared to improve the extrapolation ability of the models. In addition, it is recommended to conduct Monte Carlo simulations based on the significant covariates derived from different patient groups, and to supplement PopPK models to guide the differences in clinical efficacy between dose and traditional empirical dose, track the individualized medication effects of patients guided by PopPK models, and conduct supplementary trials based on actual clinical efficacy to facilitate the more reasonable application of models in clinical practice.

References

[1] Cordonnier C, Rovira M, Maertens J, et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: Results of the vosifi study. Haematologica, 2010, 95(10): 1762-1768. https://doi.org/10.3324/haematol.2009.020073.

[2] Mikulska M, Novelli A, Aversa F, et al. Voriconazole in clinical practice. Journal of chemotherapy (Florence, Italy), 2012, 24(6): 311-327. https://doi.org/10.1179/1973947812y.0000000051.

[3] Pappas P G, Kauffman C A, Andes D R, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of america. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 2016, 62(4): e1-50. https://doi.org/10.1093/cid/civ933.

[4] Patterson T F, Thompson G R, Denning D W, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of america. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 2016, 63(4): e1-e60. https://doi.org/10.1093/cid/ciw326.

[5] Huang C, Dong D, Yu F, et al. Evaluation of pharmacokinetics and safety with bioequivalence of voriconazole injection of 2 formulations in chinese healthy volunteers: Bioequivalence study. Clinical pharmacology in drug development, 2023, 12(5): 542-547. https://doi.org/10.1002/cpdd.1218.

[6] Takesue Y, Hanai Y, Oda K, et al. Clinical practice guideline for the therapeutic drug monitoring of voriconazole in non-asian and asian adult patients: Consensus review by the japanese society of chemotherapy and the japanese society of therapeutic drug monitoring. Clinical therapeutics, 2022, 44(12): 1604-1623. https://doi.org/10.1016/j.clinthera.2022.10.005.

[7] Chantharit P, Tantasawat M, Kasai H, et al. Population pharmacokinetics of voriconazole in patients with invasive aspergillosis: Serum albumin level as a novel marker for clearance and dosage optimization. Therapeutic drug monitoring, 2020, 42(6): 872-879. https://doi.org/10.1097/ftd.0000000000000799.

[8] Lin X B, Li Z W, Yan M, et al. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients. British journal of clinical pharmacology, 2018, 84(7): 1587-1597. https://doi.org/10.1111/bcp.13595.

[9] Dvorackova E, Sima M, Vyskocilova K, et al. Population pharmacokinetics and covariate-based dosing individualization of voriconazole in lung transplant recipients. Journal of chemotherapy (Florence, Italy), 2023: 1-10. https://doi.org/10.1080/1120009x.2023.2219590.

[10] Schulz J, Kluwe F, Mikus G, et al. Novel insights into the complex pharmacokinetics of voriconazole: A review of its metabolism. Drug metabolism reviews, 2019, 51(3): 247-265. https://doi.org/10.1080/03602532.2019.1632888.

[11] Ullmann A J, Aguado J M, Arikan-Akdagli S, et al. Diagnosis and management of aspergillus diseases: Executive summary of the 2017 escmid-ECMM-ers guideline. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2018, 24(Suppl 1): e1-e38. https://doi.org/10.1016/j.cmi.2018.01.002.

[12] Chen K, Zhang X, Ke X, et al. Individualized medication of voriconazole: A practice guideline of the division of therapeutic drug monitoring, chinese pharmacological society. Therapeutic drug monitoring, 2018, 40(6): 663-674. https://doi.org/10.1097/ftd.0000000000000561.

[13] Bodilsen J, D'Alessandris Q G, Humphreys H, et al. European society of clinical microbiology and infectious diseases guidelines on diagnosis and treatment of brain abscess in children and adults. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2024, 30(1): 66-89. https://doi.org/10.1016/j.cmi.2023.08.016.

[14] Resztak M, Sobiak J, Czyrski A. Recent advances in therapeutic drug monitoring of voriconazole, mycophenolic acid, and vancomycin: A literature review of pediatric studies. Pharmaceutics, 2021, 13(12). https://doi.org/10.3390/pharmaceutics13121991.

[15] Kluwe F, Michelet R, Huisinga W, et al. Towards model-informed precision dosing of voriconazole: Challenging published voriconazole nonlinear mixed-effects models with real-world clinical data. Clinical pharmacokinetics, 2023, 62(10): 1461-1477. https://doi.org/10.1007/s40262-023-01274-y.

[16] Shi C, Xiao Y, Mao Y, et al. Voriconazole: A review of population pharmacokinetic analyses. Clinical pharmacokinetics, 2019, 58(6): 687-703. https://doi.org/10.1007/s40262-019-00735-7.

[17] Chaudhri K, Stocker S L, Williams K M, et al. Voriconazole: An audit of hospital-based dosing and monitoring and evaluation of the predictive performance of a dose-prediction software package. The Journal of antimicrobial chemotherapy, 2020, 75(7): 1981-1984. https://doi.org/10.1093/jac/dkaa098.

[18] Jin H, Wang T, Falcione B A, et al. Trough concentration of voriconazole and its relationship with efficacy and safety: A systematic review and meta-analysis. The Journal of antimicrobial chemotherapy, 2016, 71(7): 1772-1785. https://doi.org/10.1093/jac/dkw045.

[19] Khan-Asa B, Punyawudho B, Singkham N, et al. Impact of albumin and omeprazole on steady-state population pharmacokinetics of voriconazole and development of a voriconazole dosing optimization model in thai patients with hematologic diseases. Antibiotics (Basel, Switzerland), 2020, 9(9): https://doi.org/10.3390/antibiotics9090574.

[20] Han K, Capitano B, Bies R, et al. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients. Antimicrobial agents and chemotherapy, 2010, 54(10): 4424-4431. https://doi.org/10.1128/aac.00504-10.

[21] Han K, Bies R, Johnson H, et al. Population pharmacokinetic evaluation with external validation and bayesian estimator of voriconazole in liver transplant recipients. Clinical pharmacokinetics, 2011, 50(3): 201-214. https://doi.org/10.2165/11538690-000000000-00000.

[22] van den Born D A, Martson A G, Veringa A, et al. Voriconazole exposure is influenced by inflammation: A population pharmacokinetic model. International journal of antimicrobial agents, 2023, 61(4): 106750. https://d

Downloads

Published

2025-09-01

Issue

Vol. 7 No. 5 (2025)

Section

Articles

DOI:

https://doi.org/10.61784/ejst3111

How to Cite

Lu Yao, Wei Bu, Min Luo, Liu Shi, HongBo Xu, WenMei Liang, Yan Chen, Tao Chen, Bao Fu, Lei Gong. Group pharmacokinetics of fluconazole in patients with severe infection. Eurasia Journal of Science and Technology. 2025, 7(5): 39-55. DOI: https://doi.org/10.61784/ejst3111 .